



Published in final edited form as:

Bioorg Med Chem Lett. 2013 February 1; 23(3): 682–686. doi:10.1016/j.bmcl.2012.11.111.

Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors

Damien Y. Duveau^a, Xin Hu^a, Martin J. Walsh^a, Suneet Shukla^b, Amanda P. Skoumbourdis^a, Matthew B. Boxer^a, Suresh V. Ambudkar^b, Min Shen^a, and Craig J. Thomas^a

^aNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892, United States.

^bLaboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, United States.

Abstract

The importance of the trifluoromethyl group in the polypharmacological profile of nilotinib was investigated. Molecular editing of nilotinib led to the design, synthesis and biological evaluation of analogues where the trifluoromethyl group was replaced by a proton, fluorine and a methyl group. While these analogues were less active than nilotinib toward Abl, their activity toward Kit was comparable, with the monofluorinated analogue being the most active. Docking of nilotinib and of analogues **2a–c** to the binding pocket of Abl and of Kit showed that the lack of shape complementarity in Kit is compensated by the stabilizing effect from its juxtamembrane region.

Keywords

CML; Kit; Abl; kinase; molecular editing

The receptor tyrosine kinase Kit (also known as c-Kit, or CD117) is involved in a host of cellular processes, including cell differentiation, proliferation and survival.¹ Kit is found on the surface of hematopoietic stem cells (HSC), common myeloid progenitors, common lymphoid progenitors, myeloblasts, megakaryocytes, and mast cells. Upon binding of its ligand, the stem cell factor (SCF), the receptor dimerizes, leading to the activation of the cytoplasmic kinase domain. The phosphorylated tyrosine residues of Kit are then involved in a series of signal transduction events including the PI3K pathway, the Jak-Stat pathway, Src-family kinases, and the Ras-Erk pathway.² Gain-of-function mutations of Kit are associated with a number of cancers such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), mast cell leukemia, and gastrointestinal stromal tumors (GIST). Another cause of CML is the oncogenic breakpoint cluster region protein-abelson kinase (Bcr-Abl) fusion protein, caused by the Philadelphia chromosome.³ Bcr-Abl becomes constitutively active, and unregulated phosphorylation of proteins found in HSC leads to uncontrolled growth and survival.

2009 Elsevier Ltd. All rights reserved.

Corresponding author. Tel.: +0-301-217-4079; fax: +0-301-217-5736; craigt@mail.nih.gov.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Imatinib (Gleevec, Novartis) (Fig. 1) is an inhibitor of the Bcr-Abl fusion protein, Kit and of the receptor tyrosine kinases platelet-derived growth factor receptor subtype alpha (PDGFR α). It was approved in 2001 for the treatment of CML, and in 2003 for the treatment of GIST. Despite its success, resistance to the drug was observed in patients because of mutations of the Abl protein. The second generation kinase inhibitor nilotinib (Tasigna, Novartis) (Fig. 1) also targets Abl and Kit and was approved in 2007 for the treatment of CML. The drug was then advanced to phase III clinical for the treatment of GIST resistant to imatinib, but was discontinued in 2011 because of a lack of superior efficacy compared to the current standard of care. Understanding the polypharmacology of nilotinib (and other kinase inhibitors) is paramount to understanding their ultimate utility, and it is likely that the capacity for nilotinib to target both Abl and Kit, along with other kinases such as PDGFR α , accounts for the clinical utility of the drug. Pathway redundancy via Kit signaling, in particular, may abrogate Bcr-Abl inhibition requiring that Kit must be inhibited in addition to Bcr-Abl for efficacy to be realized.⁴

Molecular design of nilotinib (**1**) was based upon the crystal structure of the imatinib-Abl complex. Binding to the inactive form of Abl was maintained through the [4-(3-pyridinyl)-2-pyrimidinyl]aniline portion of imatinib and of nilotinib. However, nilotinib relies on fewer hydrogen-bonding interactions with amino acid residues of the hinge region of Abl, and on a larger number of hydrophobic interactions. Such van der Waals interactions are found by the 4-methyl imidazole moiety and especially by the trifluoromethyl group. In fact, structural studies have shown that one of the CF₃ fluorines interacts with the carbonyl of the Asp381 backbone in Abl.⁵ Olsen showed that protein backbone fragments H-C α -C=O provide a favorable “fluorophilic” environment for the C-F bond, including multipolar interactions between the intrinsically polar C-F and C=O bonds.⁶ A significant number of molecular probes and drug candidates targeting kinases feature a trifluoromethyl group (Fig. 2). Examples include NS187⁷ (a Bcr-Abl and Lyn kinase inhibitor), HG-7-85-01⁸ (a Bcr-Abl, Kit, PDGFR, and Src family kinase inhibitor), and sorafenib⁹ (Nevaxar, Bayer/Onyx)(a c-Raf, Kit, isoform specific VEGFR inhibitor). Since protein kinases display a high degree of homology at their active sites, ATP-competitive small molecule kinase inhibitors often possess activity against several targets. In the particular case of nilotinib, the activity profile is well established.¹⁰ In this study, we endeavored to define the influence of the trifluoromethyl group present in nilotinib with respect to its polypharmacology.

A modular synthetic sequence was developed to access nilotinib analogues (scheme 1). The syntheses of analogues **2a–c** commenced with the Ullman-type coupling between aryl iodide **3a–c** and 4-methyl-1*H*-imidazole, using a procedure developed by Buchwald et al.¹¹ Three challenges associated with this reaction were (1) the poor solubility of the reagents in the reaction mixture, (2) the lack of reactivity of the starting aryl iodide (especially **3b**), and (3) the possible isomerization of 4-methyl-1*H*-imidazole during the reaction. Using the more soluble cesium carbonate as base and polyethylene glycol as a co-solvent to acetonitrile improved the solubility of the reagents, affording a clear reaction solution when stirred at reflux. Activation of the copper catalyst with 4,7-dimethoxy-1,10-phenanthroline¹² allowed not only the reaction to proceed in higher yields than when using copper(I) iodide and ethylene diamine were used, but also led to the formation of *N*-aryl imidazoles **4a–c** as single isomers. The nitro group was reduced using tin(II) chloride-dihydrate in methanol. Formation of the amide bond between benzoic acid **6** and anilines **5a–c** was more difficult than expected. Common procedures such as EDCI or DCC coupling in DCM, DCE, or acetonitrile failed; HATU coupling in DMF was not successful either; deprotonation of the aniline using potassium *tert*-butoxide in THF, followed by treatment of the resulting anilide¹³ with the methyl ester of **6** also failed. Eventually, conversion of **6** to the corresponding acyl chloride, using thionyl chloride in the polar aprotic solvent NMP, followed by addition of anilines **5a–c** provided nilotinib analogues **2a–c**.¹⁴ The low

solubility of **5a–c** and of **6** in solvents such as DCM, DCE or THF, along with the poor reactivity of anilines **5a–c** may account for the difficulty to form the amide bond. The nature of the substitution on the aromatic ring of aryl iodide **3** had a great influence on its reactivity, as well as the reactivity of its subsequent synthetic intermediates. Thus, fluorinated aryl imidazole **4b** was consistently obtained in lower yield, as compared to **4a** and **4c**. Similarly, aniline **5b** was less reactive toward the acyl chloride of **6** in the final coupling step leading to analogue **2b**. Dilution of the reaction mixture with ice-cold water led to the precipitation of the crude products which could then be collected by filtration. The solids thus obtained were finally purified by reverse-phase HPLC.

Utilizing two commercial organizations (Reaction Biology Corp. www.reactionbiology.com and DiscoverX <http://www.kinomescan.com/>), we generated IC_{50} and K_d values for nilotinib (**1**) and analogues **2a–c** for a panel of kinases (table 1). The activity profile of nilotinib versus a broad panel of kinases had been reported by Davis et al.,¹⁵ and those results were used as a starting point in our study to focus on the kinases involved in the signaling pathways primarily targeted by nilotinib.

The results obtained in both enzymatic assays were in good agreement with those previously reported for nilotinib.¹⁶ When comparing the four compounds activities within the functional assay (table 1), nilotinib (**1**) was the most active toward Abl by a hundred fold ($IC_{50} < 2.5$ nM). The second most active analogue was methyl analogue **2c** ($IC_{50} = 135.8$ nM), followed by **2b** ($IC_{50} = 750$ nM) and **2a** ($IC_{50} = 2953$ nM). These results underscore the importance of a methyl or of a trifluoromethyl group for the binding of the compound to Abl, as reported by Manley et al.⁵ The influence of the trifluoromethyl group, and, to a lesser extent, of the methyl group was also observed for the inhibition of the discoidin domain receptor subtype 2 (DDR2), the lymphocyte-specific tyrosine kinase (LCK) and for the inhibition of LYN: once again, nilotinib was the most active compound, followed by methyl analogue **2c**. Regarding the platelet-derived growth factor receptor (PDGFR), nilotinib (**1**) and methyl analogue **2c** were the most active ($IC_{50} < 2.54$ nM and 8.20 nM respectively), compared to **2a** and **2b** ($IC_{50} < 83.87$ nM and 25.96 nM respectively). The comparative activity between methylated and non-methylated analogues was particularly noticeable with PDGFR β ($IC_{50} < 60.11$ nM for **1** and 768.4 nM for **2c** versus 35400 nM for **2a** and >50000 nM for **2b**). On the other hand, Nilotinib and analogues **2a–c** displayed good inhibitory activity toward Kit, suggesting that unlike Abl, the presence of a methyl or of a trifluoromethyl group was not required. The same structure activity relationship was observed for the four compounds versus the Fms-like tyrosine kinase 3 (FLT3), with fluorinated analogue **2c** being the most active compound ($IC_{50} = 117.8$ nM). While **2a** and **2c** displayed comparable activities ($IC_{50} = 973.9$ nM, and 882.0 nM respectively), no correlation was observed between **2c** and **1** ($IC_{50} = 9548$ nM).

The binding affinity data (table 2) showed that nilotinib (**1**) and methylated analogue **2c** displayed stronger binding affinities toward Abl ($K_d = 3.6$ nM for **1** and $K_d = 3.4$ nM for **2c**), although the K_d values for **2a** and **2b** were close. Fluorinated analogue **2b** had a stronger binding affinity than unsubstituted analogue **2a** ($K_d = 9.4$ nM for **2b** and $K_d = 29$ nM for **2a**). This result may imply the presence of van der Waals interactions between the fluorine and a carbonyl of the backbone in the hydrophobic pocket. In addition, compounds **2a** and **2b** showed the strongest affinity for Kit (4.4 nM and 3.5 nM respectively). A good correlation between the measurement of the inhibition of kinase activity (IC_{50}) and that of the thermodynamic binding affinity (K_d) was observed for Abl, Kit, DDR2, and FLT3. While the level of selectivity between compounds **1** and **2a–c** was not high in the panel of kinases tested (the K_d values were in the same order of magnitude), a remarkable difference in affinity of the fluorinated analogue toward FLT3, whereby fluorinated analogue **2b** showed a tighter binding by a factor twenty compared to the other compounds tested. This

result supports the selective inhibitory activity of **2b** as compared to the other analogues (table 1).

Taken together, those results show that the four compounds tested fell into two categories: 'methylated' analogues (**1** and **2c**) versus 'non methylated' analogues (**2a** and **2b**), each category possessing its own selectivity profile. In addition the influence of a fluorine further tuned the activity profile of the four analogues. For instance, nilotinib (**1**) is selective toward Abl and PGDFR α , while **2b** is more selective toward Kit and FLT3.

The binding modes of these nilotinib analogues to Abl and Kit were generated by docking them into the binding site followed by energy minimization refinement. As shown in figure 3, the small molecule inhibitor occupied in the ATP binding pocket of Kit^{17,18} in a similar manner as observed in the complex of Abl/nilotinib. Key interactions such as binding at the hinge region, H-bonding with the gatekeeper Thr-670 (Kit), and aromatic stacking interaction with Phe-811 of the DFG motif are typically retained in these kinases. Another remarkable binding feature associated with these compounds is that the edited group was orientated into a hydrophobic pocket at the bottom of the cleft, which is formed by a number of hydrophobic residues and highly conserved in Abl and Kit (Fig. 3). The trifluoromethyl group of nilotinib appears to fit more favorably into the pocket of Abl as compared to the proton and the fluoride substituent of compounds **2a** and **2b** that had a significantly decreased activity. Compared to Abl, the hydrophobic pocket in Kit is relatively small (estimated cavity volume is 755.4 Å³ and 822.5 Å³ for Kit and Abl, respectively), suggesting that it may have contributions to the differential activities found herein.

The binding and functional activities of nilotinib (**1**) and **2a–c** versus Kit suggest that this kinase is much more tolerant of structural deviance at this specific molecular site. The protonated compound **2a**, while retained the same activity as nilotinib to Kit, exhibited ~100 fold higher selectivity over Abl. This raised an interesting issue, as the binding interactions of **2a** in Kit and Abl are highly conserved. Further analysis indicated that Kit possesses a unique juxtamembrane region at the *N*-terminal end followed by the kinase domain, which extends to the back door of the solvent exposed region of the substrate binding pocket. It is likely that the juxtamembrane loop participates in the binding interaction by stabilizing the inhibitor in the pocket. To test this hypothesis, MD simulations were performed to investigate the dynamics of inhibitor binding. As shown in figure 4, the complex of **2a** bound to Abl exhibited high flexibility, but was significantly stabilized in the Kit binding complex. In contrast, the complexes of nilotinib in Abl and Kit were comparable and remained stable during the simulations. Therefore, a plausible explanation for the higher inhibitory activity and selectivity of these analogues to Kit is that, while the trifluoromethyl group plays a dominant role in nilotinib binding to Abl, lack of such van der Waals interaction and shape complementarity in Kit is largely compensated by the stabilizing effect from the juxtamembrane region.

To gain further insight into this possible explanation we examined nilotinib (**1**) and **2a–c** within a series of functional assays at selected, well characterized Kit mutants (D816V, D816H, T670I, V560G, V654A) (Reaction Biology Corp. www.reactionbiology.com). Residue Asp-816 lies in front of the DFG motif in the activation loop. Though it is not directly involved in the binding interactions with inhibitors, mutation of this residue with a His or Val is expected to affect the conformation of the activation loop and, consequently the binding affinity of small molecules. This was, in fact, found with each agent possessing > 1 M activity versus D816V and > 200 nM versus D816H. The gatekeeper residue Thr-670 forms a hydrogen bond and plays a vital role in inhibitor binding and each agent in this study lost activity (> 1 M) versus the T670I mutant. It is worth noting that mutant T670I, while disrupting the key H-bonding interaction, also likely poses a steric hindrance to

inhibitor in the pocket. Val-654 is found at the bottom of the binding pocket which contributes to the hydrophobic interaction. The decreased activity of these compounds (**1**, **2a** and **2c** > 1 M; **2b** > 400 nM) against the mutant V654A corroborated the importance of the hydrophobic interaction in the pocket. More interestingly, these analogues showed increased inhibitory activities to mutant V560G (nilotinib (**1**) and **2a–c** < 10 nM). Val560 lies in the juxtamembrane region and a replacement of Val to Gly may possibly make the juxtamembrane loop more flexible allowing more facile coverage of the solvent-exposed region and further stabilize inhibitor binding.

In conclusion, the influence of the trifluoromethyl group in the activity profile of nilotinib was investigated, by synthesizing analogues of nilotinib bearing a fluorine (**2b**), a methyl group (**2c**), or no substituent (**2a**) in that position. Presence of a trifluoromethyl group in nilotinib (**1**), and of a methyl group in **2c**, leads to tight fitting in Abl, and probably in DDR2 as well. Furthermore, the trifluoromethyl group allows van der Waals interactions between one of the fluorine and the one of the carbonyl backbone located in the hydrophobic pocket adjacent to the hinge region in Abl, thus further enhancing the selectivity of nilotinib toward this kinase. On the other hand, the corresponding hydrophobic pocket found in Kit is larger in size, accommodating each one of the four compounds studied. However, the role juxtamembrane region in Kit may account for the higher binding affinity of **2a** and **2b** toward Kit. Fluorinated analogue **2b** possesses a good inhibitory activity toward Kit and FLT3, and binds tightly to those two kinases. Since kinases possess a high degree of homology, taking advantage of the subtle difference between a methyl and a trifluoromethyl group, or between a proton and fluorine may allow tuning of the pharmacological profile of kinase inhibitors.


Acknowledgments

We thank Jim Bougie, Thomas Daniel and William Leister for compound purification, as well as Paul Shinn, Danielle VanLeer and Christopher LeClair for assistance with compound management. This research was supported by the Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical Research grant U54HG005033 and the Intramural Research Program of the National Human Genome Research Institute at the National Institutes of Health. S. Shukla and S.V. Ambudkar were supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.


References and notes

1. Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. *Stem Cells*. 2005; 23:16. [PubMed: 15625120]
2. Roskoski R. *Biochem. Biophys. Res. Commun.* 2005; 337:1. [PubMed: 16129412]
3. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. *Ann. Intern. Med.* 2003; 138:819. [PubMed: 12755554]
4. Belloc F, Airiau K, Jeanneteau M, Garcia M, Guerin E, Lippert E, Moreau-Gaudry F, Mahon FX. *Leukemia*. 2009; 23:679. [PubMed: 19158834]
5. Manley PW, Cowan-Jacob SW, Fendrich G, Mestan J. *Blood*. 2005; 106:940A.
6. Olsen JA, Banner DW, Seiler P, Wagner B, Tschopp T, Obst-Sander U, Kansy M, Müller K, Diederich F. *ChemBioChem*. 2004; 5:666. [PubMed: 15122639]
7. Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi K, Maekawa T. *Blood*. 2005; 106:3948. [PubMed: 16105974]
8. Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley PW, Adamia S, Wu C, Gray N, Griffin JD. *Blood*. 2010; 115:4206. [PubMed: 20299508]
9. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M,

- Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. *Cancer Res.* 2004; 64:7099. [PubMed: 15466206]
10. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. *Br. J. Cancer.* 2006; 94:1765. [PubMed: 16721371]
 11. Altman RA, Koval ED, Buchwald SL. *J. Org. Chem.* 2007; 72:6190. [PubMed: 17625886]
 12. Altman RA, Buchwald SL. *Org. Lett.* 2006; 8:2779. [PubMed: 16774255]
 13. Ueda S, Su MJ, Buchwald SL. *J. Am. Chem. Soc.* 2012; 134:700. [PubMed: 22126442]
 14. Analogue **2a** ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.54 (s, 1H), 9.53 (s, 1H), 9.28 (s, 1H), 9.17 (s, 1H), 8.70 (d, *J* = 4.8 Hz, 1H), 8.55 (d, *J* = 5.1 Hz, 1H), 8.48 (d, *J* = 8.0 Hz, 1H), 8.32 (t, *J* = 2.1 Hz, 1H), 8.29 (d, *J* = 1.9 Hz, 1H), 7.95 (s, 1H), 7.81 (d, *J* = 8.4 Hz, 1H), 7.75 (d, *J* = 7.9 Hz, 1H), 7.61 (t, *J* = 8.1 Hz, 1H), 7.58 – 7.52 (m, 1H), 7.49 (d, *J* = 5.1 Hz, 1H), 7.47 (m, 1H), 7.44 (d, *J* = 8.4 Hz, 1H), 2.36 (s, 3H), 2.36 (s, 3H). Analogue **2b** ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.69 (s, 1 H), 9.52 (d, *J* = 1.8 Hz, 1 H), 9.30 (d, *J* = 1.6 Hz, 1 H), 9.19 (s, 1 H), 8.72 (dd, *J* = 4.8, 1.5 Hz, 1 H), 8.56 (d, *J* = 5.1 Hz, 1 H), 8.51 (ddd, *J* = 8.2, 2.0, 1.8 Hz, 1 H), 8.30 (d, *J* = 1.8 Hz, 1 H), 8.12 (m, 1 H), 7.95 (m, 1 H), 7.79 (m, 1 H), 7.75 (dd, *J* = 8.0, 2.0 Hz, 1 H), 7.59 (dd, *J* = 8.1, 4.8 Hz, 1 H), 7.50 (d, *J* = 5.3 Hz, 1 H), 7.49 (dt, *J* = 9.4, 2.2 Hz, 1 H), 7.45 (d, *J* = 8.2 Hz, 1 H), 2.36 (s, 3 H), 2.35 (s, 3 H). Analogue **2c** ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.45 (s, 1H), 9.52 (s, 1H), 9.28 (s, 1H), 9.16 (s, 1H), 8.71 (m, 1H), 8.55 (d, *J* = 5.1 Hz, 1H), 8.48 (d, *J* = 7.9 Hz, 1H), 8.28 (d, *J* = 1.9 Hz, 1H), 8.12 (m, 1H), 7.94 (m, 1H), 7.74 (m, 1H), 7.65 (s, 1H), 7.55 (m, 1H), 7.49 (d, *J* = 5.2 Hz, 1H), 7.44 (d, *J* = 7.6 Hz, 1H), 7.32 (s, 1H), 2.40 (s, 3H), 2.35 (s, 6H).
 15. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. *Nat. Biotech.* 2011; 29:1046.
 16. Manley PW, Cowan-Jacob SW, Fendrich G, Jahnke W, Fabbro D. *Blood.* 2008; 118:727.
 17. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang B-C, Wilson KP. *J. Biol. Chem.* 2004; 279:31655. [PubMed: 15123710]
 18. Mol CD, Lim KB, Sridhar V, Zou H, Chien EYT, Sang B-C, Nowakowski J, Kassel DB, Cronin CN, McRee DE. *J. Biol. Chem.* 2003; 278:31461. [PubMed: 12824176]




Imatinib




Nilotinib (1)


Figure 1.
Structure of imatinib and of nilotinib




NS-187



Nilotinib (1)



HG-7-85-01



Sorafenib

Figure 2.
Structures of kinase inhibitors bearing a trifluoromethyl group




Figure 3. Predicted binding mode from AutoDock: (A) compound **2c** bound in the active site of Abl, (B) nilotinib bound in Kit and (C) structural overlay of the hydrophobic pocket between Kit and Abl. Compound **2a** is illustrated in the binding complex. Residues of Abl are labeled in green and residues of Kit are labeled in black. Surface of the binding pocket of Abl is colored in cyan and the surface of Kit is colored in yellow.





Figure 4. RMSD plot of the inhibitor binding complexes with (A) Abl and (B) Kit from MD simulations.



Scheme 1.
Syntheses of analogues **2a-c**

Table 1Inhibitory activities of compounds **1** and **2a–c**

Kinase	Compound IC ₅₀ (nM) ^a			
	1	2a	2b	2c
Abl	<2.54	2953	749.8	135.8
Kit	14.70	32.50	9.96	54.94
DDR2	<2.54	653.3	178.6	17.22
FLT3	9548	973.9	117.8	882.0
LCK	108.2	44620	11050	1448
LYN	1281	45420	15150	3534
PDGFR α	<2.54	83.87	25.96	8.20
PDGFR β	60.11	35400	>5000	768.4

^a Assay details are provided by Reaction Biology Corp. via the internet at www.reactionbiology.com

Table 2Dissociation constants of compounds **1** and **2a–c**

Kinase	Compound K_d (nM) ^a			
	1	2a	2b	2c
Abl	3.6	29	9.4	3.4
Kit	17	4.4	3.5	14
DDR2	6.2	320	14	5.6
FLT3	40000	1400	58	1200
PDGFR α	74	14	24	65
PDGFR β	16	7.2	8.5	12

^a Assay details are provided by Reaction Biology Corp. via the internet at <http://www.kinomescan.com/>.